Pharmaceutical Effect of Manganese Porphyrins on Manganese Superoxide Dismutase Deficient Mice

Mice lacking manganese-superoxide dismutase (Mn-SOD) activity exhibit typical pathology of dilated cardiomyopathy (DCM). In the present study, the structure–activity relationship between the water-soluble manganese (Mn) porphyrin with SOD activity and the in vivo pharmaceutical effect on DCM is repo...

Full description

Saved in:
Bibliographic Details
Published inMolecular pharmaceutics Vol. 9; no. 10; pp. 2956 - 2959
Main Authors Hayakawa, Natsumi, Asayama, Shoichiro, Noda, Yoshihiro, Shimizu, Takahiko, Kawakami, Hiroyoshi
Format Journal Article
LanguageEnglish
Published United States American Chemical Society 01.10.2012
Subjects
Animals
Cardiomyopathy, Dilated - drug therapy
Cardiomyopathy, Dilated - metabolism
Manganese - pharmacology
Metalloporphyrins - pharmacology
Mice
Oxidative Stress - drug effects
Structure-Activity Relationship
Superoxide Dismutase - deficiency
Superoxide Dismutase - metabolism
Water - chemistry
water-soluble manganese porphyrin
superoxide dismutase mimic
antioxidative therapy
manganese superoxide dismutase deficient mice
dilated cardiomyopathy
Online AccessGet full text

Cover

More Information
Summary:Mice lacking manganese-superoxide dismutase (Mn-SOD) activity exhibit typical pathology of dilated cardiomyopathy (DCM). In the present study, the structure–activity relationship between the water-soluble manganese (Mn) porphyrin with SOD activity and the in vivo pharmaceutical effect on DCM is reported. The Mn-SOD-deficient mice were treated with Mn-porphyrins for 3 weeks. The treatment of a Mn-porphyrin, MnM2Py2P, suppressed the progression of cardiac dilation. These results suggest that the Mn-porphyrin MnM2Py2P treatment is proposed as a potential therapy for DCM.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1543-8384
1543-8392
DOI:10.1021/mp300147v